[{"quiz_id": "ABMS20260101_kimi-k2-thinking_p02", "question_id": "ABMS20260101_kimi-k2-thinking_p02-001", "question": "A 35-year-old man develops DRESS syndrome 3 weeks after starting phenytoin. He has fever, eosinophilia, atypical lymphocytosis, and transaminitis (AST 450 U/L). HHV-6 PCR becomes positive at day 16 of illness. What is the clinical significance of this virologic finding?", "options": ["Confirms phenytoin as the causative drug", "Indicates need for ganciclovir antiviral therapy", "Predicts higher risk of disease flare and organ damage", "Represents asymptomatic viral reactivation without prognostic value", "Suggests alternative diagnosis of acute HHV-6 infection"], "answer": "C", "answer_index": 2, "explanation": "HHV-6 reactivation at weeks 2-3 in DRESS is pathogenically linked to disease severity, predicting higher risk of relapse, end-organ damage, and prolonged course. It indicates need for more aggressive immunosuppression, not antiviral therapy, as the virus is a marker of immune dysregulation.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Dermatology", "abms_specialty": "Dermatology", "abms_source": "topics_mapped", "source_label_raw": "Dermatology", "source_quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "source_question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-010", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251205T080918850Z_kimi-k2-thinking_seed126", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026_backup/20251205T080918850Z_kimi-k2-thinking_seed126.jsonl", "pred": "C", "model_outputs": "Here is a step-by-step analysis of the question and options:\n\n1.  Diagnosis: The patient presents with classic signs of DRESS syndrome (Drug Reaction with Eosinophilia and Systemic Symptoms), also known as Drug-Induced Hypersensitivity Syndrome (DiHS). The features include drug exposure (phenytoin), delayed onset (3 weeks), fever, rash, eosinophilia, atypical lymphocytosis, and organ involvement (hepatitis).\n\n2.  The Role of HHV-6: A unique and hallmark feature of DRESS/DiHS, particularly distinguishing it from other severe cutaneous adverse reactions, is the sequential reactivation of latent herpesviruses. HHV-6 is the most frequently reactivated virus, typically occurring 2 to 4 weeks after the onset of the drug eruption (consistent with day 16 in the scenario).\n\n3.  Analyzing the Option Significance:\n    *   A. Confirms phenytoin as the causative drug: Incorrect. HHV-6 reactivation is a feature of the DRESS syndrome pathophysiology regardless of the specific aromatic anticonvulsant or other triggering drug (e.g., allopurinol, sulfonamides). It does not identify the specific drug.\n    *   B. Indicates need for ganciclovir antiviral therapy: Incorrect. The mainstay of treatment for DRESS is the withdrawal of the offending drug and the administration of systemic corticosteroids. While the viral reactivation contributes to the pathology, antiviral therapy (like ganciclovir) is not standard of care unless there is specific, severe viral end-organ damage (e.g., encephalitis) unresponsive to immune modulation. Routine use is not recommended due to toxicity and the primary immune-mediated nature of the syndrome.\n    *   C. Predicts higher risk of disease flare and organ damage: Correct. The reactivation of HHV-6 in DRESS is clinically significant because it is strongly associated with a more severe disease course, a \"stuttering\" or prolonged recovery, and \"flares\" of symptoms (fever, hepatitis, rash) even after the offending drug has been discontinued and steroids have been started. It is also associated with a higher risk of long-term autoimmune sequelae (e.g., thyroiditis, Type 1 diabetes).\n    *   D. Represents asymptomatic viral reactivation without prognostic value: Incorrect. As noted above, it carries significant prognostic value regarding severity and chronicity.\n    *   E. Suggests alternative diagnosis of acute HHV-6 infection: Incorrect. Primary HHV-6 infection (Roseola) typically occurs in infancy. In this adult patient with a clear drug trigger and DRESS phenotype, the finding represents reactivation, not a primary alternative diagnosis.\n\nConclusion: The detection of HHV-6 reactivation in DRESS syndrome serves as a marker for a severe, protracted clinical course often characterized by relapses or flares of systemic inflammation.\n\nThe answer is (C)"}, {"quiz_id": "ABMS20260101_kimi-k2-thinking_p02", "question_id": "ABMS20260101_kimi-k2-thinking_p02-002", "question": "A 58-year-old kidney transplant recipient (deceased donor, 8 months post-transplant) presents with rising creatinine from 1.2 to 2.1 mg/dL. Plasma BK virus PCR is 18,000 copies/mL. Allograft biopsy shows Banff class B BK virus nephropathy. Current immunosuppression: tacrolimus 5 mg twice daily (trough 8 ng/mL), mycophenolate mofetil 1000 mg twice daily, prednisone 5 mg daily. What is the first immunosuppression modification?", "options": ["Reduce tacrolimus dose by 50%", "Reduce mycophenolate mofetil by 50%", "Discontinue tacrolimus and switch to cyclosporine", "Discontinue mycophenolate mofetil completely", "Reduce prednisone to 2.5 mg daily"], "answer": "B", "answer_index": 1, "explanation": "For BK viremia >10,000 copies/mL with Banff class B nephropathy, first-line therapy is mycophenolate dose reduction by 50% or complete discontinuation. Tacrolimus reduction is second-line if viremia persists after 2-4 weeks. This sequence preserves tacrolimus (the cornerstone immunosuppressant) while reducing the antiproliferative agent that most impairs viral clearance. Steroids should not be reduced initially.", "generator_model": "kimi-k2-thinking", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Urology", "abms_specialty": "Urology", "abms_source": "target_topic", "source_label_raw": "Urology", "source_quiz_id": "20251225T234023630Z_kimi-k2-thinking_seed133", "source_question_id": "20251225T234023630Z_kimi-k2-thinking_seed133-005", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251225T234023630Z_kimi-k2-thinking_seed133", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251225T234023630Z_kimi-k2-thinking_seed133.jsonl", "pred": "B", "model_outputs": "The patient is a renal transplant recipient with biopsy-proven BK virus nephropathy (Banff class B) and BK viremia. The cornerstone of management for BK virus nephropathy is the reduction of immunosuppression to allow the host immune system to clear the virus.\n\nCurrent guidelines (e.g., AST Infectious Disease Community of Practice, KDIGO) recommend a stepwise approach to reducing immunosuppression. While institutional protocols vary, the most commonly accepted first step is to reduce the antimetabolite (mycophenolate mofetil) dose.\n\nA typical algorithm is:\n1.  Reduce mycophenolate mofetil (MMF) dose by 50%.\n2.  If viral load persists or increases after 2-4 weeks, discontinue MMF completely.\n3.  If viremia still persists, reduce the calcineurin inhibitor (tacrolimus) trough target (e.g., to 4-6 ng/mL).\n\nAnalyzing the options:\n*   A. Reduce tacrolimus dose by 50%: A 50% dose reduction is drastic and could lead to sub-therapeutic levels (current trough is 8 ng/mL, 50% dose cut might drop it to ~4 ng/mL or lower, risking rejection). CNI reduction is usually a secondary step or done more conservatively (titrating to a lower target) rather than a blind 50% dose cut as the first move.\n*   B. Reduce mycophenolate mofetil by 50%: This is the standard, prudent first modification. It lowers the overall immunosuppressive burden, specifically targeting the agent (MMF) that is often implicated in facilitating viral replication, while maintaining a baseline of immunosuppression to prevent acute rejection.\n*   C. Discontinue tacrolimus and switch to cyclosporine: Switching agents is not the first-line intervention; reduction is preferred.\n*   D. Discontinue mycophenolate mofetil completely: Discontinuing MMF is a valid strategy but is often the second step in the stepwise algorithm. Stopping it immediately carries a higher risk of precipitating acute rejection compared to a 50% reduction, particularly giving the 8-month post-transplant timing.\n*   E. Reduce prednisone to 2.5 mg daily: Reducing steroids has a negligible effect on viral clearance compared to MMF or Tacrolimus reduction and risks adrenal insufficiency or rejection.\n\nTherefore, reducing the mycophenolate mofetil dose by 50% is the best initial step.\n\nThe answer is (B)"}, {"quiz_id": "ABMS20260101_kimi-k2-thinking_p02", "question_id": "ABMS20260101_kimi-k2-thinking_p02-003", "question": "A 55-year-old man has left vocal fold paralysis 6 months after thyroidectomy, with persistent aspiration and breathy voice. EMG shows absent motor unit potentials. What is the optimal injection laryngoplasty material?", "options": ["A) Hyaluronic acid gel for temporary medialization", "B) Calcium hydroxylapatite paste for permanent augmentation", "C) Autologous fat injection for long-term volume restoration", "D) Gelfoam paste for temporary 3-month effect", "E) Polydimethylsiloxane for permanent irreversible medialization"], "answer": "B", "answer_index": 1, "explanation": "For permanent vocal fold paralysis with absent EMG potentials, calcium hydroxylapatite provides durable medialization without migration. Its high viscosity prevents particle dispersion, and it integrates into tissue without foreign body reaction. Hyaluronic acid and Gelfoam are temporary (<6 months) and unsuitable for permanent paralysis. Autologous fat has unpredictable resorption (50-80% at 1 year), and polydimethylsiloxane risks granuloma formation and airway compromise if overinjected.", "generator_model": "kimi-k2-thinking", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Otolaryngology", "abms_specialty": "Otolaryngology", "abms_source": "target_topic", "source_label_raw": "Otolaryngology", "source_quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed130", "source_question_id": "20251221T010349114Z_kimi-k2-thinking_seed130-016", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251221T010349114Z_kimi-k2-thinking_seed130", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251221T010349114Z_kimi-k2-thinking_seed130.jsonl", "pred": "B", "model_outputs": "This patient presents with left vocal fold paralysis of 6 months' duration following a thyroidectomy. The key to ensuring the correct management choice lies in the interpretation of the electromyography (EMG) findings and the timeline.\n\n1.  Prognosis Assessment:\n    *   Timeline: 6 months post-injury is a critical juncture. While some spontaneous recovery can occur up to 12 months, the likelihood decreases significantly after 6 months.\n    *   EMG Findings: \"Absent motor unit potentials\" (MUPs) indicates complete denervation with no signs of reinnervation (which would be suggested by polyphasic potentials). This confirms a poor prognosis for spontaneous recovery, essentially diagnosing the paralysis as permanent.\n\n2.  Treatment Goals:\n    *   Since the paralysis is permanent and the patient has significant symptoms (aspiration, breathy voice), a durable or permanent solution is required.\n    *   The question asks specifically for the *optimal injection laryngoplasty material*. While laryngeal framework surgery (Type I thyroplasty) is the gold standard for permanent paralysis, the question confines the choice to injection materials.\n\n3.  Evaluating the Options:\n    *   A) Hyaluronic acid gel: A temporary material (lasts 3-6 months). This would be the optimal choice if the EMG showed signs of reinnervation (polyphasic potentials) or if the prognosis was uncertain. Given the confirmed denervation, a temporary filler is not optimal.\n    *   B) Calcium hydroxylapatite (CaHA): A long-lasting (semi-permanent) material, typically staying in the vocal fold for 12-24 months or longer. It is widely considered the optimal \"off-the-shelf\" injection material for patients with permanent paralysis who either decline framework surgery or need a durable solution. It offers excellent viscoelastic properties and biocompatibility without the risks associated with permanent silicone or Teflon injections.\n    *   C) Autologous fat: A long-term option, but it requires a harvesting procedure (liposuction), has unpredictable resorption rates (requiring overcorrection), and is technique-sensitive. It is generally considered less \"optimal\" than CaHA for pure injection laryngoplasty in a board-exam context due to these variables and morbidity.\n    *   D) Gelfoam: Extremely temporary (4-6 weeks). Only useful for very short-term diagnostic trials or expected rapid recovery.\n    *   E) Polydimethylsiloxane (Silicone): A permanent material, but it is associated with a higher risk of granuloma formation and late complications compared to CaHA. It is generally less favored than CaHA or thyroplasty in modern practice.\n\nConclusion: Since the patient has permanent paralysis (confirmed by EMG) and requires injection laryngoplasty, a material that provides long-term augmentation with a good safety profile is required. Calcium hydroxylapatite is the standard choice for this indication.\n\nThe answer is (B)"}, {"quiz_id": "ABMS20260101_kimi-k2-thinking_p02", "question_id": "ABMS20260101_kimi-k2-thinking_p02-004", "question": "A 45-year-old man with T6 complete spinal cord injury has a stage 4 sacral pressure ulcer with positive probe-to-bone test and MRI showing marrow edema limited to cortex. He has been on antibiotics for 4 weeks with minimal improvement. What is definitive management?", "options": ["A) Continue suppressive antibiotics indefinitely with wound care", "B) Surgical debridement to bone with burr drilling, VAC therapy, then gluteal myocutaneous flap", "C) Radical debridement with partial sacrectomy and omental flap", "D) Transcutaneous bone biopsy and targeted IV antibiotics for 12 weeks", "E) Osteomyelitis excision with free latissimus dorsi muscle flap"], "answer": "B", "answer_index": 1, "explanation": "Stage 4 sacral ulcer with cortical osteomyelitis requires surgical debridement with burr drilling of exposed bone to bleeding cortex, followed by VAC therapy to prepare granulation tissue, then gluteal myocutaneous flap coverage. This achieves 85% healing rates. Partial sacrectomy is reserved for medullary involvement. Suppressive antibiotics alone fail in 70% of cases, and free flaps are unnecessary when local muscle is available and viable.", "generator_model": "kimi-k2-thinking", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Physical Medicine and Rehabilitation", "abms_specialty": "Physical Medicine and Rehabilitation", "abms_source": "target_topic", "source_label_raw": "Physical Medicine and Rehabilitation", "source_quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed130", "source_question_id": "20251221T010349114Z_kimi-k2-thinking_seed130-017", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251221T010349114Z_kimi-k2-thinking_seed130", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251221T010349114Z_kimi-k2-thinking_seed130.jsonl", "pred": "B", "model_outputs": "This patient has a chronic Stage 4 pressure injury with osteomyelitis (indicated by positive probe-to-bone and MRI) that has failed conservative management (antibiotics).\n\n1.  Diagnosis and Status: The patient has chronic osteomyelitis underlying a large soft tissue defect. Antibiotics alone are generally unable to penetrate the necrotic bone and biofilm effectively enough to cure chronic osteomyelitis in this setting, nor do they close the large wound.\n2.  Surgical Principles: The standard definitive management for Stage 4 pressure ulcers with osteomyelitis in a surgical candidate involves:\n    *   Debridement: Excision of the ulcer, pseudocapsule, and necrotic tissue.\n    *   Ostectomy: Removal of the infected bone. Since the MRI shows edema limited to the cortex, partial ostectomy or decortication (often done with an oscillating saw, osteotome, or burr) is appropriate to reach healthy bleeding bone.\n    *   Coverage: Obliteration of dead space and coverage with well-vascularized tissue.\n3.  Flap Selection: For sacral ulcers, the gluteus maximus myocutaneous flap is the workhorse flap for reconstruction because of its proximity, bulk, and robust blood supply.\n4.  Evaluation of Options:\n    *   A: Suppressive antibiotics are palliative or used when surgery is contraindicated. They are not definitive management for a young, otherwise treatable patient.\n    *   B: This option outlines the standard surgical sequence: debridement of bone (appropriate for cortical involvement), negative pressure wound therapy (VAC) often used to prepare the wound bed, followed by a local myocutaneous flap (gluteal) for closure.\n    *   C: Radical sacrectomy is reserved for very extensive/deep infections or malignancy and carries high morbidity (spinal instability, hemorrhage). An omental flap requires a laparotomy and is rarely a first-line choice for sacral sores.\n    *   D: Biopsy and antibiotics alone do not address the large soft tissue defect or the necrotic bone sequestrum effectively.\n    *   E: A free latissimus dorsi flap is a complex microsurgical procedure. According to the reconstructive ladder, local flaps (like the gluteal flap) should be used before free flaps.\n\nThe answer is (B)"}, {"quiz_id": "ABMS20260101_kimi-k2-thinking_p02", "question_id": "ABMS20260101_kimi-k2-thinking_p02-005", "question": "A 71-year-old man with history of scalp radiation for basal cell carcinoma 20 years ago develops a 5 cm recurrent tumor with 2 cm calvarial erosion. After oncologic resection, there is a full-thickness calvarial defect with dural exposure. What is the optimal reconstruction?", "options": ["A) Latissimus dorsi myocutaneous free flap with split-thickness skin graft", "B) Omental free flap with vascularized bone graft", "C) Pericranial flap rotation with split calvarial graft", "D) Latissimus dorsi muscle-only free flap with skin graft and delayed cranioplasty", "E) Anterolateral thigh fasciocutaneous flap with titanium mesh"], "answer": "D", "answer_index": 3, "explanation": "In irradiated scalp defects with calvarial exposure, muscle-only free flaps (latissimus dorsi) provide robust vascularity to compromised beds while allowing secondary skin grafting. The muscle conforms better to calvarial contours than fasciocutaneous flaps, and delayed cranioplasty after soft tissue healing reduces hardware exposure risk. Myocutaneous flaps are too bulky, and local pericranial flaps have unreliable vascularity in previously irradiated fields.", "generator_model": "kimi-k2-thinking", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Plastic Surgery", "abms_specialty": "Plastic Surgery", "abms_source": "target_topic", "source_label_raw": "Plastic Surgery", "source_quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed130", "source_question_id": "20251221T010349114Z_kimi-k2-thinking_seed130-008", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251221T010349114Z_kimi-k2-thinking_seed130", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251221T010349114Z_kimi-k2-thinking_seed130.jsonl", "pred": "D", "model_outputs": "This question describes a complex scalp reconstruction scenario involving a Recurrent Basal Cell Carcinoma (BCC) in a previously irradiated field. The key factors influencing the decision are the history of radiation, the presence of a recurrent tumor, the full-thickness calvarial defect with dural exposure, and the goal of optimal functional and aesthetic reconstruction.\n\n1.  History of Radiation and Recurrence: The scalp tissue surrounding the defect is compromised (fibrotic, poorly vascularized) due to prior radiation. This makes local flaps (like a pericranial flap, Option C) unreliable and prone to necrosis. A free flap is indicated to bring healthy, well-vascularized tissue into the wound bed.\n2.  Flap Choice: While both Latissimus Dorsi (LD) and Anterolateral Thigh (ALT) flaps are used for scalp reconstruction, the specific configuration matters.\n    *   LD Myocutaneous (Option A): Includes skin and fat, which is often too bulky for the scalp, leading to poor cosmetic results (\"hamburger\" appearance).\n    *   Alt Fasciocutaneous (Option E): Can also be bulky and harder to contour precisely to the dural surface compared to muscle, though it is a valid option.\n    *   LD Muscle-Only with STSG (Option D): This is considered a \"workhorse\" for large, complex scalp defects. The muscle conforms excellently to the dura (obliterating dead space), and over time, the muscle atrophies, providing a thin contour that closely mimics the natural thickness of the scalp.\n3.  Calvarial Management: The patient has a recurrent tumor in a radiated bed. Placing foreign material (like Titanium mesh in Option E) immediately carries a significant risk of infection and extrusion. The safest \"optimal\" approach in a high-risk bed (recurrence + radiation) is to obtain stable soft tissue coverage first. The cranioplasty can be performed as a delayed secondary procedure once the oncologic outcome is secured and the soft tissue envelope is healed and stable. For smaller bone defects (implied by a 2 cm erosion, though the resection defect is larger), delayed repair is well-tolerated.\n4.  Contraindications:\n    *   Option B (Omentum): Generally reserved for salvage when other options aren't available; requires laparotomy.\n    *   Option C (Pericranial): High risk of failure due to prior radiation field.\n\nTherefore, the Latissimus Dorsi muscle-only free flap provides healthy vascularized tissue that contours well, and delaying the cranioplasty avoids the complications associated with primary alloplastic reconstruction in a hostile wound bed.\n\nThe answer is (D)"}, {"quiz_id": "ABMS20260101_kimi-k2-thinking_p02", "question_id": "ABMS20260101_kimi-k2-thinking_p02-006", "question": "A 28-year-old woman presents with progressive myelopathy over 6 months. MRI shows a holocord enhancing lesion from C2 to T9 with cystic components. Intraoperative neuromonitoring shows 60% amplitude reduction in motor evoked potentials after initial tumor debulking. What is the next surgical decision?", "options": ["A) Continue aggressive debulking despite signal changes", "B) Halt resection, perform duraplasty, and plan staged resection", "C) Switch to ultrasonic aspiration for gentler tumor removal", "D) Administer high-dose steroids and continue resection", "E) Perform en bloc resection of involved cord segments"], "answer": "B", "answer_index": 1, "explanation": "For holocord ependymoma, intraoperative neuromonitoring with >50% MEP amplitude reduction mandates immediate cessation of resection to prevent permanent neurologic deficit. Staged resection after allowing neural recovery (typically 3-6 months) achieves maximal safe cytoreduction. Continuing despite signal loss causes paraplegia, while en bloc resection is contraindicated in holocord lesions. Ultrasonic aspiration still transmits vibratory injury to compressed neural tissue.", "generator_model": "kimi-k2-thinking", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Neurological Surgery", "abms_specialty": "Neurological Surgery", "abms_source": "target_topic", "source_label_raw": "Neurological Surgery", "source_quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed130", "source_question_id": "20251221T010349114Z_kimi-k2-thinking_seed130-009", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251221T010349114Z_kimi-k2-thinking_seed130", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251221T010349114Z_kimi-k2-thinking_seed130.jsonl", "pred": "B", "model_outputs": "Here is the analysis of the clinical scenario:\n\n1.  Clinical Picture: The patient has a holocord intramedullary spinal cord tumor (likely an ependymoma or astrocytoma given the description) spanning from C2 to T9. This is a massive lesion.\n2.  Intraoperative Event: There is a 60% reduction in Motor Evoked Potential (MEP) amplitude. In intraoperative neuromonitoring (IONM), a decrease in MEP amplitude of greater than 50% is generally considered a significant warning criterion indicating potential injury to the corticospinal tracts.\n3.  Management of IONM Alerts: The standard protocol when a significant MEP drop occurs is to immediately stop surgical manipulation, irrigate with warm saline, increase mean arterial pressure (MAP) to improve perfusion, and wait for signal recovery.\n4.  Decision Making:\n    *   Option A, C, and D all involve continuing the resection. Continuing resection while MEPs are significantly depressed (>50% drop) carries a very high risk of permanent neurological deficit (paralysis). Switching instruments or giving steroids does not negate the need to stop causing the trauma that led to the signal drop.\n    *   Option E involves resecting the spinal cord itself (\"involved cord segments\"), which would result in high quadriplegia and is contrary to the goal of preserving function.\n    *   Option B is the correct management. If signals do not return to baseline or an acceptable level after pausing and corrective measures, the safest course of action—especially in a massive holocord tumor—is to halt the resection. A duraplasty is performed to accommodate postoperative swelling (which can effectively act as a decompression). A staged resection allows the spinal cord to recover from the surgical insult, and the remaining tumor can be addressed in a second surgery.\n\nTherefore, halting the resection to prevent permanent injury is the priority.\n\nThe answer is (B)"}, {"quiz_id": "ABMS20260101_kimi-k2-thinking_p02", "question_id": "ABMS20260101_kimi-k2-thinking_p02-007", "question": "A 62-year-old man with T2N0M0 glottic carcinoma involving the anterior commissure is scheduled for definitive radiation therapy. He has good performance status and no comorbidities. What is the optimal fractionation scheme to maximize local control?", "options": ["A) 70 Gy in 35 fractions over 7 weeks with concurrent cisplatin", "B) 66 Gy in 33 fractions over 6.5 weeks with concurrent cetuximab", "C) 72 Gy in 42 fractions using concomitant boost over 6 weeks", "D) 60 Gy in 30 fractions over 6 weeks with hyperfractionation", "E) 50 Gy in 20 fractions over 4 weeks with hypofractionation"], "answer": "C", "answer_index": 2, "explanation": "For T2 glottic cancer with anterior commissure involvement, altered fractionation with concomitant boost (72 Gy/42 fractions/6 weeks) improves 5-year local control to 85% versus 70% with standard fractionation, without increasing late toxicity. The anterior commissure is a sanctuary site with poor vascularity, requiring higher biologically effective dose. Concurrent chemotherapy is not indicated for T2 disease and increases mucositis. Hypofractionation is reserved for early T1 lesions without commissure involvement.", "generator_model": "kimi-k2-thinking", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Radiation Oncology", "abms_specialty": "Radiation Oncology", "abms_source": "target_topic", "source_label_raw": "Radiation Oncology", "source_quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed130", "source_question_id": "20251221T010349114Z_kimi-k2-thinking_seed130-020", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251221T010349114Z_kimi-k2-thinking_seed130", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251221T010349114Z_kimi-k2-thinking_seed130.jsonl", "pred": "C", "model_outputs": "This question addresses the management of early-stage (T2N0M0) glottic carcinoma, specifically focusing on the optimal radiation fractionation scheme to maximize local control.\n\n1.  Patient & Disease characteristics: The patient has a T2N0M0 glottic carcinoma. Involvement of the anterior commissure is a known adverse prognostic factor for local control, often causing T2 tumors to have higher recurrence rates than T1 or T2 without such involvement.\n2.  Standard of Care: The standard treatment for T2N0 glottic cancer is definitive radiation therapy or transoral laser microsurgery (in select cases). For radiation, altered fractionation (hyperfractionation or acceleration) has been shown to improve local control compared to standard fractionation (70 Gy in 7 weeks).\n3.  Evaluating the Options:\n    *   A) 70 Gy in 35 fractions over 7 weeks with concurrent cisplatin: Chemotherapy is generally not indicated for T2N0 (Stage II) glottic cancer. It increases toxicity without a proven survival or local control benefit in this early stage. Concurrent chemotherapy is standard for locally advanced (Stage III/IV) disease.\n    *   B) 66 Gy in 33 fractions over 6.5 weeks with concurrent cetuximab: Similar to cisplatin, cetuximab (biotherapy) is reserved for locally advanced or recurrent/metastatic disease, not T2N0.\n    *   C) 72 Gy in 42 fractions using concomitant boost over 6 weeks: This option describes a standard concomitant boost (accelerated fractionation) regimen (e.g., typically 1.8 Gy once daily for the large field plus a 1.5 Gy boost as a second daily fraction during the last 2-2.5 weeks). The RTOG 9003 trial demonstrated that altered fractionation (including concomitant boost) improves locoregional control compared to standard fractionation in head and neck cancer. Specifically for T2 glottic cancer, the RTOG 9512 trial showed that hyperfractionation significantly improved local control compared to standard fractionation. While RTOG 9512 used a pure hyperfractionation schedule (1.2 Gy BID to 79.2 Gy), the concomitant boost regimen in Option C is a valid, high-dose, accelerated schedule designed to overcome tumor repopulation and maximize control, and it is the only option listed that provides a therapeutic intensity superior to standard fractionation without adding contraindicated systemic therapy.\n    *   D) 60 Gy in 30 fractions over 6 weeks with hyperfractionation: Measurements of 2 Gy per fraction constitute standard fractionation sizing, not hyperfractionation (which uses <1.8 Gy, typically 1.2 Gy). Furthermore, a total dose of 60 Gy is considered sub-therapeutic for T2 glottic cancer (standard is 70 Gy).\n    *   E) 50 Gy in 20 fractions over 4 weeks with hypofractionation: While hypofractionation (e.g., 63 Gy in 28 fractions or 55 Gy in 20 fractions) is a standard of care, a dose of 50 Gy in 20 fractions (2.5 Gy/fx) results in a biologically effective dose (BED) that is too low for definitive cure of a T2 carcinoma. (Note: 50 Gy in 16 fractions is a regimen for T1, and 55 Gy in 20 fractions is a UK regimen for T2, but 50 Gy in 20 fractions is insufficient).\n\nTherefore, Option C represents the most appropriate and effective *radiation-only* intensification strategy listed to maximize local control for a high-risk T2 tumor.\n\nThe answer is (C)"}, {"quiz_id": "ABMS20260101_kimi-k2-thinking_p02", "question_id": "ABMS20260101_kimi-k2-thinking_p02-008", "question": "A 68-year-old man is 18 days post-Ivor Lewis esophagectomy with gastric conduit reconstruction for stage III esophageal adenocarcinoma. He develops sudden onset cough with swallowing, respiratory distress, and sepsis. Chest CT demonstrates a 5 mm fistula between the gastric conduit and right mainstem bronchus at the level of the carina, with surrounding mediastinal air and fluid. Bronchoscopy confirms the fistula with conduit mucosa visible. What is the definitive management?", "options": ["A) Endoscopic placement of overlapping esophageal and airway stents", "B) Emergency right thoracotomy with fistula repair using intercostal muscle flap and conduit resection with cervical esophagostomy", "C) NPO status, total parenteral nutrition, and broad-spectrum antibiotics for 6 weeks", "D) Bronchoscopic application of fibrin glue and continued enteral feeding via jejunostomy", "E) Cervical esophagostomy and conduit abandonment without fistula repair"], "answer": "B", "answer_index": 1, "explanation": "Early postoperative tracheobronchial-gastric conduit fistula requires urgent surgical repair with viable muscle flap reinforcement; conduit ischemia at the anastomotic line necessitates conduit resection and delayed reconstruction. Endoscopic stenting has >80% failure rate in this setting due to conduit tension and ongoing contamination.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Thoracic Surgery", "abms_specialty": "Thoracic Surgery", "abms_source": "target_topic", "source_label_raw": "Thoracic Surgery", "source_quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "source_question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-001", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251221T010349114Z_kimi-k2-thinking_seed131", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251221T010349114Z_kimi-k2-thinking_seed131.jsonl", "pred": "B", "model_outputs": "This patient presents with a gastro-bronchial fistula (acquired airway-conduit fistula) 18 days after an Ivor Lewis esophagectomy. This is a life-threatening complication characterized by the triad of cough with swallowing, respiratory distress, and sepsis. The presence of mediastinal air and fluid confirms mediastinitis.\n\nThe management strategy is dictated by the patient's clinical status (sepsis) and the nature of the defect.\n1.  Sepsis and Mediastinitis: The patient is septic, indicating that the mediastinal contamination is uncontained and systemic. Immediate source control is required. Conservative management (Option C) or fibrin glue (Option D) is inadequate and would lead to mortality.\n2.  Airway Defect: There is a 5 mm hole in the right mainstem bronchus. This must be repaired to prevent continued aspiration pneumonia and allow for mechanical ventilation if necessary. Direct mucosal repair is often insufficient due to inflammation/necrosis, so a vascularized tissue flap (intercostal muscle, serratus, etc.) is the standard of care to buttress the repair and separate the airway from the mediastinum.\n3.  Conduit Status: In the early postoperative period (within 30 days), a fistula to the airway generally implies significant conduit ischemia, necrosis, or a large anastomotic dehiscence that has eroded into the bronchus. Because the patient is septic and the local tissue is compromised, attempting to save the conduit is extremely hazardous. Stenting (Option A) might \"cover\" the defect, but stenting a gastric conduit is technically difficult (size mismatch, migration risk) and does not drain the mediastinal sepsis or remove the necrotic source. Stenting is often reserved for patients who are not surgical candidates or for palliative intent (malignant fistulas).\n\nDefinitive Management:\nThe standard surgical \"damage control\" for an early postoperative airway fistula with sepsis involves:\n*   Emergency Thoracotomy: To access the chest and drain the infection.\n*   Fistula Repair with Muscle Flap: To seal the airway defect with healthy vascularized tissue.\n*   Conduit Resection (or exclusion) and Cervical Esophagostomy: To remove the source of the leak (the compromised conduit) and divert saliva away from the chest (spit fistula).\n\nLater, after the patient recovers from sepsis and the nutritional status is optimized (often months later), esophageal continuity can be restored (e.g., colonic interposition).\n\nOption E is incorrect because leaving the airway fistula unrepaired is fatal. Option A is less definitive than surgery in a septic patient with a potentially necrotic conduit.\n\nThe answer is (B)\n\nThe answer is (B)"}, {"quiz_id": "ABMS20260101_kimi-k2-thinking_p02", "question_id": "ABMS20260101_kimi-k2-thinking_p02-009", "question": "A 72-year-old man has a 5.5 cm infrarenal abdominal aortic aneurysm with a thick circumferential rind of periaortic inflammation, bilateral ureteral obstruction with hydronephrosis, and elevated ESR (85 mm/hr) and CRP (120 mg/L). What is the optimal management sequence?", "options": ["A) Immediate open surgical repair with prednisone 1 mg/kg", "B) Endovascular aortic repair (EVAR) then prednisone 1 mg/kg", "C) Prednisone 40 mg daily for 6 weeks then open surgical repair", "D) Prednisone 40 mg daily for 6 weeks then EVAR", "E) Prednisone alone without aortic repair"], "answer": "D", "answer_index": 3, "explanation": "Inflammatory AAA requires initial steroid therapy to reduce periaortic inflammation and relieve ureteral obstruction. Delayed EVAR is preferred over open repair due to severe periaortic inflammation that increases surgical morbidity. Steroids alone risk aneurysm rupture.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Vascular Surgery", "abms_specialty": "Vascular Surgery", "abms_source": "target_topic", "source_label_raw": "Vascular Surgery", "source_quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "source_question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-012", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251221T010349114Z_kimi-k2-thinking_seed131", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251221T010349114Z_kimi-k2-thinking_seed131.jsonl", "pred": "B", "model_outputs": "This patient presents with an Inflammatory Abdominal Aortic Aneurysm (IAAA), characterized by the triad of a thickened aneurysm wall, perianeurysmal fibrosis (involving the ureters in this case), and elevated inflammatory markers (ESR, CRP).\n\nHere is the logic for determining the optimal management:\n\n1.  Indication for Repair: The aneurysm is 5.5 cm, which meets the standard size threshold for repair in men to prevent rupture. Furthermore, the aneurysm is symptomatic (implied by the active inflammation and ureteral obstruction), which typically mandates urgent rather than delayed repair.\n2.  Modality of Repair (EVAR vs. Open):\n    *   Open Repair: In IAAA, open repair is technically hazardous due to the \"hostile\" retroperitoneum. The inflammatory rind obliterates tissue planes, making dissection difficult and increasing the risk of injury to the duodenum, vena cava, and ureters. Historically, a course of preoperative steroids (Option C) was recommended to reduce this inflammation prior to open surgery (\"cooling off\" period).\n    *   EVAR: Endovascular Aortic Repair is currently the preferred treatment for IAAA if the anatomy is suitable. It effectively excludes the aneurysm, preventing rupture. Studies have consistently shown that excluding the pulsatile mass with EVAR leads to the regression of the periaortic inflammation and fibrosis, often resolving ureteral obstruction without the need for difficult dissection (ureterolysis).\n3.  Role of Steroids:\n    *   While EVAR alone often leads to regression of symptoms and hydronephrosis, in patients with significant systemic symptoms or severe obstruction, corticosteroids may be used as an adjunct.\n    *   Timing: Because EVAR does not require dissection of the inflamed tissue, there is no technical benefit to delaying the procedure for a course of steroids (Option D). Delaying repair for 6 weeks in a 5.5 cm aneurysm leaves the patient at risk of rupture. Therefore, immediate repair is indicated.\n    *   Sequence: The optimal sequence is to secure the aneurysm immediately via EVAR. If inflammation or obstruction persists, or to manage the acute phase, steroids can be administered. Option B describes this \"Repair first\" approach with adjunctive medical management, avoiding the high morbidity of immediate open repair (Option A) and the rupture risk of delayed repair (Options C and D).\n\nTherefore, Endovascular aortic repair (EVAR) then prednisone is the most appropriate management to address both the rupture risk and the inflammatory complications with the lowest procedural risk.\n\nThe answer is (B)"}, {"quiz_id": "ABMS20260101_kimi-k2-thinking_p02", "question_id": "ABMS20260101_kimi-k2-thinking_p02-010", "question": "An 18-year-old male with genetically confirmed Danon disease (LAMP2 mutation) presents with severe hypertrophic cardiomyopathy (septal thickness 28 mm), ventricular pre-excitation (WPW pattern on ECG), and recurrent syncope. Electrophysiology study identifies three distinct accessory pathways. Despite maximal medical therapy, he continues to have pre-excited atrial fibrillation. What is the most appropriate next management step?", "options": ["A) Initiate flecainide therapy", "B) Perform catheter ablation of all accessory pathways", "C) Increase beta-blocker dosage", "D) Evaluate for heart transplantation", "E) Implant a dual-chamber pacemaker"], "answer": "D", "answer_index": 3, "explanation": "Danon disease causes rapidly progressive HCM, multiple accessory pathways, and skeletal myopathy with poor prognosis. Catheter ablation is often unsuccessful due to rapid pathway recurrence and progressive myocardial involvement. Beta-blockers and verapamil are contraindicated in WPW with pre-excited AF. Flecainide may transiently suppress pathways but doesn't alter disease course. Early heart transplant evaluation is recommended given the high mortality from arrhythmias and heart failure.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Cardiovascular", "abms_specialty": "Cardiovascular", "abms_source": "topics_mapped", "source_label_raw": "cardiology", "source_quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "source_question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-003", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251205T080918850Z_kimi-k2-thinking_seed124", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026_backup/20251205T080918850Z_kimi-k2-thinking_seed124.jsonl", "pred": "D", "model_outputs": "This question describes a patient with Danon disease, a rare X-linked lysosomal storage disorder caused by a mutation in the *LAMP2* gene. The clinical presentation of an 18-year-old male with severe hypertrophic cardiomyopathy (HCM), ventricular pre-excitation (WPW), and recurrent syncope is classic for this condition.\n\nAnalysis of the Clinical Scenario:\n1.  Danon Disease Characteristics: In males, Danon disease is characterized by rapidly progressive cardiomyopathy (typically hypertrophic early on, progressing to dilated/burn-out phase), skeletal myopathy, and intellectual disability. The prognosis is extremely poor in males, with death occurring at a mean age of ~19 years due to heart failure or sudden cardiac death (SCD).\n2.  Arrhythmia: The patient has WPW with multiple accessory pathways, which is a hallmark of Danon disease (and *PRKAG2* mutations). He has pre-excited atrial fibrillation (AF) refractory to medical therapy. Pre-excited AF is a life-threatening arrhythmia that can degenerate into ventricular fibrillation.\n3.  Myocardial Substrate: The patient has severe septal hypertrophy (28 mm). The myocardial architecture is disrupted by glycogen and autophagic vacuoles. This makes catheter ablation technically challenging, with lower success rates and higher recurrence rates compared to the general population. The presence of *three* distinct pathways further complicates the procedural success and increases the risk of complications (e.g., complete heart block requiring pacing, which is poorly tolerated).\n\nEvaluation of Options:\n*   A) Initiate flecainide therapy: Contraindicated. Flecainide is a Class IC antiarrhythmic that should not be used in patients with structural heart disease (especially severe LVH/HCM) due to the risk of proarrhythmia and increased mortality (CAST trial data extrapolation).\n*   B) Perform catheter ablation of all accessory pathways: While ablation is the standard treatment for drug-refractory WPW in structurally normal hearts, the context here is different. In Danon disease, ablation is often difficult due to multiple pathways and myocardial thickening. Moreover, fixing the arrhythmia does not address the underlying, rapidly progressive cardiomyopathy which is the primary driver of mortality in this age group. While it might be attempted as a palliative/temporizing measure, it is not the most appropriate *strategic* management step given the disease severity.\n*   C) Increase beta-blocker dosage: The patient is already on maximal therapy. Further increases are unlikely to be effective for the accessory pathway (which may not be responsive to AV nodal blockade) and could precipitate hemodynamic collapse in a patient with severe obstruction or stiff ventricle.\n*   D) Evaluate for heart transplantation: This is the correct answer. Given the patient's age (18), severe hypertrophy (28 mm), recurrent syncope (high risk of SCD), and resistance to medical therapy, he is in the end-stage phase of the disease. The natural history of Danon disease in males involves death in the second or third decade. Heart transplantation is the only definitive therapy that alters the prognosis. Guidelines and expert consensus emphasize early evaluation for transplantation in males with Danon disease, particularly when signs of severe cardiomyopathy or refractory arrhythmia are present.\n*   E) Implant a dual-chamber pacemaker: A pacemaker treats bradycardia, not pre-excited atrial fibrillation. It would not prevent rapid conduction over the accessory pathway.\n\nConclusion:\nWhile the arrhythmia is urgent, the underlying disease process is lethal and advanced. The complexity of the substrate (3 pathways, massive hypertrophy) makes ablation less likely to be curative or safe. The definitive and necessary step to save the patient's life is heart transplantation.\n\nThe answer is (D)"}]